basic transcription factor 3 like 4 pseudogene 4Genealiases: []
Q-omics provides the consensus-scored BTF3L4P4 profile across patient tissues and cancer cell-line models. BTF3L4P4 expression is associated with patient survival in 7 of 34 cancer types, with the highest sampling consensus in ESCA. Among the 18 cancer types available for tumor–normal comparison, BTF3L4P4 is differentially expressed in 3, with the highest sampling consensus in UCEC. Additionally, BTF3L4P4 RNA expression shows 5,786 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight ESCA, UCEC, and STAD as cancer lineages where BTF3L4P4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for BTF3L4P4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes BTF3L4P4 survival associations across molecular data types. BTF3L4P4 RNA expression shows survival associations in the most cancer types (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible BTF3L4P4 RNA expression–survival associations across cancer types. High BTF3L4P4 expression shows unfavorable associations in ESCA, LUSC, THCA and BLCA, but favorable associations in LUAD and SKCM. The ESCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .003). Together, the overview and detailed table identify ESCA as the clearest survival context for BTF3L4P4 RNA expression.
This table summarizes BTF3L4P4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for BTF3L4P4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. BTF3L4P4 shows lower tumor expression in THCA and higher tumor expression in UCEC and HNSC. The UCEC box plot shows higher BTF3L4P4 RNA expression in tumor versus normal tissue (log2 FC = +0.420, t-test p = .013).
This table shows molecular features associated with BTF3L4P4 in patient tissues and cancer cell lines. In patient samples, BTF3L4P4 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
